RZLT Rezolute, Inc.
XNAS
4.05
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
RZLT
$4.05
—
What changed
Recent filings, trades and movesKey stats
$4.05
- 52-Week Range
- $1.07 – $11.16
- YTD
- +87.07%
- IV Rank (30D)
- 30.98
- Straddle Price
- $1.32
- P/C Vol Ratio
- 0.34
- Market Cap
- $0.4B
- Open
- $4.10
- Day Range
- $3.99 – $4.10
- Volume
- 11,050
- Prev Close
- $4.02
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.84% |
| Beta vs SPY | 0.89 |
| Cost of Equity (CAPM) | 9.27% (VRP-adj) |
| WACC | 9.38% |
| Volatility Risk Premium | +147.2pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -77.1% |
| Book / Price | 24.9% |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $4.12 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $3.93 |
| Bollinger Width / SMA20 | 24.0% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: APGE, CGON, DFTX, DNTH, MBX, ORKA, TRAX, XENE
60-Day Conviction
63%
20-Day Fair Value
≈ by Dec 9, 2026
$4.02
α +0.0%
rank 61%
conviction
1%
40-Day Fair Value
≈ by Jan 7, 2027
$4.17
α +3.8%
rank 68%
conviction
90%
60-Day Fair Value
≈ by Feb 5, 2027
$4.12
α +2.6%
rank 73%
conviction
63%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $5.89 | 39% | median 6.1× · 7 peers |
| Peer P/S | n/a | 0% | |
| Market Anchor (SMA50) | $4.12 | 61% | stability 30% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-11-10 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.4B
- Employees
- 58
- List Date
- 2011-12-23
- CIK
- 0001509261
- Last Earnings
- Nov 5 after close · +6.6% vs ±48.1% expected
- Next Earnings
- ~Feb 11, 2027 (estimated)
- Headquarters
- Redwood City, CA
- Homepage
- https://www.rezolutebio.com
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 25.25% | -10.59% | 36.70% | 8.37% | 1.94% | 54.27% | 19.32% |
| Feb | -26.52% | -45.17% | -10.47% | 66.67% | -15.46% | -0.93% | -5.31% |
| Mar | -36.05% | 25.65% | -24.71% | 41.67% | -29.95% | -2.87% | -4.38% |
| Apr | -6.58% | 4.97% | 1.71% | 10.74% | 28.77% | 2.24% | 6.98% |
| May | 43.07% | -27.27% | 1.43% | 46.01% | 4.04% | 0.00% | 11.21% |
| Jun | 8.11% | 14.13% | 0.51% | 4.62% | 5.56% | 44.04% | 12.83% |
| Jul | -18.48% | -10.32% | -7.65% | 6.61% | 34.62% | -4.24% | 0.09% |
| Aug | -16.87% | -23.47% | -18.64% | 7.94% | 21.29% | -4.48% | -5.71% |
| Sep | -18.71% | 18.61% | -9.59% | 3.19% | 31.10% | -8.00% | 2.77% |
| Oct | -15.79% | -38.32% | -23.39% | 19.39% | -1.17% | -2.95% | -10.37% |
| Nov | -22.09% | -0.30% | -24.68% | -8.36% | 6.81% | 3.61%* | -7.50% |
| Dec | 2.80% | 27.78% | 23.05% | -3.92% | -74.26% | -- | -4.91% |
| Total | -68.40% | -65.67% | -53.92% | 440.32% | -50.34% | 84.99% | 47.83% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $3.89
SMA 50: $4.10
SMA 200: $3.92
Current: $4.10
EMA 12: $3.96
EMA 26: $4.02
MACD: -0.0559 | Signal: 0.0228
BEARISH
ADX (14): 12.38
RANGE
+DI: 23.95
−DI: 21.75
Momentum Oscillators
RSI (14): 52.26
NEUTRAL
Stoch %K: 55.78
Stoch %D: 46.05
Williams %R: -30.91
Volume & Volatility
BB Upper: $4.23
BB Lower: $3.56
NEUTRAL
OBV: -1,992,001
Vol SMA 20: 1,278,492
Vol ROC: -99.56%
ATR: $0.30
True Range: $0.08
HV 20: 72.7%
HV 30: 73.7%
HV 60: 64.7%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-12T00:00:00 – 2026-11-10T00:00:00
AI Analysis
Written before RZLT’s Nov 5 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary
This report provides a comprehensive stock analysis of RZLT (Rezolute, Inc.) based on technical indicators, options metrics, beta analysis, market data, and recent news headlines. The overall assessment is NEUTRAL with a confidence level of 6 out of 10.
Key drivers include the company's participation in upcoming investor conferences, which could generate positive sentiment. Primary risks are related to the stock's high volatility, negative news sentiment, and potential regulatory issues.
The investment thesis is that RZLT's recent news headlines suggest a range-bound trading environment, with potential for increased volatility around earnings announcements.
Recent news sentiment has been negative, driven by trial failures and lead asset setbacks. However, the company's participation in investor conferences could shift this sentiment positively.
Technical Analysis
Trend Direction: The short-term trend is NEUTRAL, while the medium-term trend is BEARISH. The long-term trend remains UPTRENDING.
Support/Resistance Levels: Key price levels are $3.25 (SMA 20), $3.19 (SMA 50), and $3.07 (Bollinger Bands Lower).
Momentum Signals:
- RSI interpretation: NEUTRAL (52.76)
- MACD signal: BULLISH (0.01 / Signal: 0.00 / Histogram: 0.01)
- Bollinger Bands position: NEUTRAL (price touching middle band)
Volume Analysis: Volume trends indicate a range-bound trading environment, with low institutional interest.
News & Sentiment Analysis
Recent Headlines Summary: The news headlines suggest a negative sentiment, driven by trial failures and lead asset setbacks. However, the company's participation in investor conferences could shift this sentiment positively.
Sentiment Assessment: Aggregate news sentiment is NEGATIVE.
Catalyst Identification: Upcoming investor conferences and potential earnings announcements could generate positive catalysts.
Market Narrative: The recent news headlines contradict the technical signals, indicating a range-bound trading environment with potential for increased volatility around earnings announcements.
Risk & Volatility Assessment
Beta Interpretation: Beta is 1.00 (vs SPY), indicating above-average volatility and amplification of market movements.
Volatility Regime: Current volatility is HIGH (1.24), which may persist due to recent news headlines and market uncertainty.
Options Market Signals: IV Rank is LOW (15.2%), suggesting historical low volatility, while the put/call volume ratio is BEARISH (40.67).
Downside Protection: Support levels are $3.25 (SMA 20) and $3.19 (SMA 50), with potential for a bounce if the stock reaches these levels.
Market Context & Positioning
Sector Performance: RZLT's sector is performing NEUTRALLY, which may impact its trading range.
Institutional Activity: Low institutional interest suggests a lack of support or resistance from larger investors.
Correlation Analysis: The stock moves with the market (0.10), indicating an amplification of market movements.
Relative Valuation: RZLT is trading within its historical range, with potential for increased volatility around earnings announcements.
Key Levels & Action Items
Critical Price Levels: Support levels are $3.25 (SMA 20) and $3.19 (SMA 50), while resistance is at the upper Bollinger Bands level ($3.42).
Breakout/Breakdown Levels: A breakout above the upper Bollinger Bands level could generate a bullish signal, while a breakdown below the lower Bollinger Bands level could indicate increased selling pressure.
Time-Sensitive Catalysts: Upcoming investor conferences and earnings announcements could generate positive catalysts.
Risk Management: Stop-loss levels should be set at $3.19 (SMA 50), with position sizing considerations based on recent news headlines and market uncertainty.
By analyzing the technical indicators, options metrics, beta analysis, market data, and recent news headlines, this report provides a comprehensive assessment of RZLT's stock performance and potential for future price movements. The report highlights key drivers, primary risks, and catalysts that could impact the stock's trading range.
Generated
News
All RZLT news →
Earnings History
9 of 9 under expected move
Avg Expected Move
29.18%
Avg Actual Move
5.41%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-09-19 | After-Close | 41.49% | 5.39% | 0.13x | Within |
| 2024-11-07 | After-Close | 21.42% | 2.45% | 0.11x | Within |
| 2025-02-12 | After-Close | 15.95% | 1.03% | 0.06x | Within |
| 2025-05-13 | After-Close | 34.06% | 4.90% | 0.14x | Within |
| 2025-09-17 | After-Close | 14.92% | 6.36% | 0.43x | Within |
| 2025-11-06 | After-Close | 29.95% | 12.08% | 0.40x | Within |
| 2026-02-12 | After-Close | 33.06% | 5.79% | 0.18x | Within |
| 2026-05-12 | Pre-Market | 23.66% | 4.10% | 0.17x | Within |
| 2026-11-05 | After-Close | 48.08% | 6.59% | 0.14x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
RZLT Options Activity & IV Rank
RZLT IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 147.8%
7-DTE IV: —
Expected Move: $1.32
7-DTE Move: $8.25
Days to Exp: 37 (2026-12-18)
Options Flow · All expiries
Call Volume: 3,462
Put Volume: 1,180
P/C Volume: 0.341
BULLISH
Call OI: 34,299
Put OI: 3,052
P/C OI: 0.089
Total OI: 37,351
ATM Options Pricing
ATM Call: $0.42
ATM Put: $0.90
Call %: 10.5%
Put %: 22.2%
Chain Summary
Chain Volume: 4,642
Chain OI: 37,351
Last Updated: 11/11/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 61st percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
61%
vs own history
GEX tilt
+0.95
OI-weighted, today
Vanna tilt
+0.89
δ-sensitivity to IV
Charm tilt
-1.00
δ-decay vs time
Vanna tilt +0.89: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -1.00: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 5 ATM contracts, 7k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)31.0MediumNov 11
Straddle Price (30 DTE)$1.32Nov 11
Beta Analysis
Risk Metrics
Beta: 1.2183
Alpha: 55.37%
Correlation: 0.1309
R-Squared: 1.7%
Stock Volatility: 127.2%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own RZLT
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $2.7M | #2414 of 3716 | -65.9% | 13F | |
| Citadel Hedge fund Ken Griffin | $512K | #4440 of 6285 | -14.7% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
RZLT Institutional Ownership (13F)
Filings for 2026-06-30 · 41 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 103,907,114 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
8 filers$15.60M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $7.77M | 49.83% | 2026-06-30 |
| 2 | Squadron Capital Management LLC | $4.68M | 30.00% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $957.32K | 6.14% | 2026-06-30 |
| 4 | Centiva Capital, LP | $822.64K | 5.27% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $679.37K | 4.36% | 2026-09-30 |
| 6 | Caption Management, LLC | $520.00K | 3.33% | 2026-06-30 |
| 7 | GROUP ONE TRADING LLC Custodian | $115.96K | 0.74% | 2026-06-30 |
| 8 | IMC-Chicago, LLC Custodian | $51.75K | 0.33% | 2026-09-30 |
4 filers$994.06K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $488.28K | 49.12% | 2026-06-30 |
| 2 | Simplex Trading, LLC Custodian | $295.18K | 29.69% | 2026-09-30 |
| 3 | Citadel Advisors LLC Custodian | $208.00K | 20.92% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $2.60K | 0.26% | 2026-06-30 |
RZLT Insider Trading (Form 4)
Latest: 2026-10-23Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-23 | Daron Evans | CFO | Gift (G) | −8,000 | — | EDGAR | |
| 2026-09-03 | Sunil Ratilal Karnawat | Chief Commercial Officer | Tax (F) | −2,267 | $4.50 | -$10.2K | EDGAR |
| 2026-07-07 | Brian Kenneth Roberts | Chief Medical Officer | Tax (F) | −3,062 | $4.99 | -$15.3K | EDGAR |
| 2026-07-07 | Nevan C Elam | CEO | Tax (F) | −8,004 | $4.99 | -$39.9K | EDGAR |
| 2026-07-07 | Daron Evans | CFO | Tax (F) | −3,062 | $4.99 | -$15.3K | EDGAR |
| 2026-03-04 | Nevan C Elam | CEO | Tax (F) | −27,618 | $2.99 | -$82.6K | EDGAR |
| 2026-03-04 | Brian Kenneth Roberts | Chief Medical Officer | Tax (F) | −11,439 | $2.99 | -$34.2K | EDGAR |
| 2026-03-04 | Daron Evans | CFO | Tax (F) | −11,438 | $2.99 | -$34.2K | EDGAR |
| 2025-12-17 | Brian Kenneth Roberts | Chief Medical Officer | Buy (P) | +28,000 | $1.70 | $47.6K | EDGAR |
| 2025-12-17 | Wladimir Hogenhuis | Director | Buy (P) | +5,650 | $1.69 | $9.5K | EDGAR |
| 2025-12-15 | Sunil Ratilal Karnawat | Chief Commercial Officer | Buy (P) | +12,100 | $1.62 | $19.6K | EDGAR |
| 2025-12-15 | Nevan C Elam | CEO | Buy (P) | +32,000 | $1.59 | $50.9K | EDGAR |
| 2025-12-15 | Daron Evans | CFO | Buy (P) | +45,000 | $1.77 | $79.6K | EDGAR |
| 2025-11-21 | Erik Harris | Director | Award (A) | +21,000 | — | EDGAR | |
| 2025-11-21 | Philippe Fauchet | Director | Award (A) | +21,000 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
RZLT Insider Holdings
10 insiders · @ $4.02
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Young-Jin Kim | Director | 8,594,336 | $34.55M | $9.37M | 6 | 2025-11-21 |
| 2 | Nevan C Elam | CEO | 605,497 | $2.43M | $94.3K | 12 | 2026-07-07 |
| 3 | Daron Evans | CFO | 415,400 | $1.67M | $664.7K | 20 | 2026-10-23 |
| 4 | Brian Kenneth Roberts | Chief Medical Officer | 309,351 | $1.24M | $247.4K | 21 | 2026-07-07 |
| 5 | Wladimir Hogenhuis | Director | 119,675 | $481.1K | $261.3K | 11 | 2025-12-17 |
| 6 | Gil M Labrucherie | Director | 109,072 | $438.5K | $400.0K | 8 | 2025-11-21 |
| 7 | Sunil Ratilal Karnawat | Chief Commercial Officer | 71,173 | $286.1K | $19.6K | 4 | 2026-09-03 |
| 8 | Nerissa Kreher | Director | 58,576 | $235.5K | $10.0K | 7 | 2025-11-21 |
| 9 | Philippe Fauchet | Director | 55,500 | $223.1K | $0 | 6 | 2025-11-21 |
| 10 | Erik Harris | Director | 21,000 | $84.4K | $0 | 2 | 2025-11-21 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
RZLT Board & Officers
As of SEC filings through Oct 23, 2026Directors 7
- Nevan C Elam · since Jan 31, 2013
- Young-Jin Kim · since Feb 11, 2019
- Gil M Labrucherie · since Nov 20, 2019
- Philippe Fauchet · since Sep 10, 2020
- Nerissa Kreher · since Mar 3, 2021
- Wladimir Hogenhuis · since Mar 3, 2021
- Erik Harris · since Mar 25, 2025
Officers 4
- Nevan C Elam · Chief Executive Officer · since Jan 31, 2013
- Daron Evans · CFO · since Jan 22, 2024
- Brian Kenneth Roberts · Chief Medical Officer · listed since Jul 2023
- Sunil Ratilal Karnawat · Chief Commercial Officer · since Aug 18, 2025
Changes in the last 10 years (19)
| Aug 18, 2025 | Sunil Ratilal Karnawat became Chief Commercial Officer |
| Mar 25, 2025 | Erik Harris became a director |
| Mar 19, 2024 | Handok, Inc. first listed as a director in an SEC filing |
| Jan 22, 2024 | Daron Evans became CFO |
| Jul 6, 2023 | Brian Kenneth Roberts listed as Chief Medical Officer (previously Sr VP, Clinic Development) in SEC filings |
| Mar 3, 2021 | Wladimir Hogenhuis became a director |
| Mar 3, 2021 | Nerissa Kreher became a director |
| Oct 23, 2020 | Brian Kenneth Roberts became Sr VP, Clinic Development |
| Sep 10, 2020 | Philippe Fauchet became a director |
| Nov 20, 2019 | Junghee Lim became a director |
| Nov 20, 2019 | Gil M Labrucherie became a director |
| Mar 4, 2019 | Seline E. Miller became VP Finance & CAO |
| Feb 11, 2019 | Young-Jin Kim became a director |
| Feb 11, 2019 | Young Chul Sung became a director |
| Jan 30, 2019 | Handok, Inc. became a 10% owner |
| Jan 30, 2019 | Genexine Inc. became a 10% owner |
| May 10, 2018 | Keith A. Vendola became Chief Financial Officer |
| Apr 23, 2018 | XOMA Corp became a 10% owner |
| Jan 18, 2017 | Hoyoung Huh first listed as Chairman, Scientific Adv. Bd. in an SEC filing |
Not reported recently (12)
- Handok, Inc. · Last reported as a 10% owner in an SEC filing dated Mar 19, 2024
- Genexine Inc. · Last reported as a 10% owner in an SEC filing dated Jul 28, 2021
- Junghee Lim · Last reported as a director in an SEC filing dated Dec 9, 2019
- Sankaram Mantripragada · Last reported as Chief Scientific Officer in an SEC filing dated Sep 16, 2019
- Keith A. Vendola · Last reported as Chief Financial Officer in an SEC filing dated Sep 16, 2019
- Young Chul Sung · Last reported as a director in an SEC filing dated Mar 8, 2019
- Seline E. Miller · Last reported as VP Finance & CAO in an SEC filing dated Mar 7, 2019
- XOMA Corp · Last reported as a 10% owner in an SEC filing dated Apr 30, 2018
- David F Welch · Last reported as a director in an SEC filing dated Mar 15, 2017
- Hoyoung Huh · Last reported as a director in an SEC filing dated Jan 18, 2017
- Morgan Fields · Last reported as Chief Accounting Officer in an SEC filing dated Jan 13, 2017
- Barry Michael Sherman · Last reported as a director in an SEC filing dated Jan 13, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-09-24 | 0001104659-26-110420 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-11-05 | 0001104659-26-123364 | EDGAR |
ETF Holders
38 ETFs hold RZLT
25 shown · $40.39M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $11.4M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $8.0M | $77.8B | 2026-11-09 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $3.7M | — | 2026-09-30 |
| 4 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.02% | $2.5M | $14.1B | 2026-11-09 |
| 5 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.01% | $1.9M | — | 2026-08-31 |
| 6 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.01% | $1.9M | — | 2026-09-30 |
| 7 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.01% | $1.8M | — | 2026-11-09 |
| 8 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.02% | $1.5M | $6.8B | 2026-11-09 |
| 9 | JSML Janus Henderson Small Cap Growth Alpha ETF | Janus | 0.27% | $1.0M | $377.9M | 2026-11-09 |
| 10 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.08% | $922,229 | $1.2B | 2026-11-09 |
| 11 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.05% | $890,657 | — | 2026-11-09 |
| 12 | VHT Vanguard Health Care ETF | Vanguard | 0.00% | $786,559 | — | 2026-09-30 |
| 13 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.01% | $610,593 | — | 2026-11-09 |
| 14 | SBIO ALPS Medical Breakthroughs ETF | Nport | 0.23% | $558,846 | — | 2026-08-31 |
| 15 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.05% | $493,607 | $1.1B | 2026-11-09 |
| 16 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $470,364 | $95.3B | 2026-11-09 |
| 17 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.00% | $384,732 | $14.1B | 2026-11-09 |
| 18 | BBC Virtus Biotech Clinical Trials Etf | Nport | 0.79% | $366,768 | — | 2026-07-31 |
| 19 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $292,225 | — | 2026-08-31 |
| 20 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.02% | $258,063 | — | 2026-09-30 |
| 21 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $194,286 | — | 2026-11-09 |
| 22 | RUSC Russell Investments U.S. Small Cap Equity ETF | Nport | 0.23% | $179,972 | — | 2026-06-30 |
| 23 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $152,113 | — | 2026-11-10 |
| 24 | DFAU Dimensional US Core Equity Market ETF | Dimensional | 0.00% | $76,034 | $12.9B | 2026-11-09 |
| 25 | DXUV Dimensional US Vector Equity ETF | Dimensional | 0.00% | $74,691 | — | 2026-11-09 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.76
TTM Revenue
$0.00
TTM Net Income
$-77.59M
TTM Op. Cash Flow
$-64.64M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q4 '26 | 2026-06-30 | $0.00 | $-20.49M | $-0.20 | $-13.15M |
| Q3 '26 | 2026-03-31 | — | $-16.17M | $-0.16 | $-13.73M |
| Q2 '26 | 2025-12-31 | — | $-22.77M | $-0.22 | $-20.32M |
| Q1 '26 | 2025-09-30 | — | $-18.15M | $-0.18 | $-17.43M |
| Q4 '25 | 2025-06-30 | $0.00 | $-24.39M | $-0.26 | $-22.00M |
| Q3 '25 | 2025-03-31 | — | $-18.91M | $-0.27 | $-17.40M |
| Q2 '25 | 2024-12-31 | — | $-15.73M | $-0.22 | $-13.67M |
| Q1 '25 | 2024-09-30 | — | $-15.38M | $-0.22 | $-16.01M |
| Q4 '24 | 2024-06-30 | — | $-22.98M | $-0.44 | $-18.52M |
| Q3 '24 | 2024-03-31 | — | $-17.05M | $-0.34 | $-15.24M |
| Q2 '24 | 2023-12-31 | — | $-13.91M | $-0.27 | $-13.02M |
| Q1 '24 | 2023-09-30 | — | $-14.52M | $-0.28 | $-10.59M |
Q4 2026 • period ending 2026-06-30 • filed 2026-09-24
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
4.15
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-77.1%
ROA
-68.8%
Div Yield
0.00%
FCF Yield
-15.47%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$417.71M
as of 2026-11-10
RZLT vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| APGE Apogee Therapeutics, Inc. Common Stock | $10.2B | — | — | +78.2% | — |
| ORKA Oruka Therapeutics, Inc. Common Stock | $6.9B | — | — | +287.3% | 40 |
| CGON CG Oncology, Inc. Common stock | $6.7B | — | +666.0% | +73.8% | 97 |
| DNTH Dianthus Therapeutics, Inc. Common Stock | $5.1B | — | −60.8% | +123.8% | 76 |
| DFTX Definium Therapeutics, Inc. Common Share | $4.8B | — | — | +125.2% | 18 |
| XENE Xenon Pharmaceuticals Inc | $3.9B | — | — | −7.0% | 44 |
| MBX MBX Biosciences, Inc. Common Stock | $2.6B | — | — | +84.4% | 78 |
| TRAX First Tracks Biotherapeutics, Inc. Ordin | $2.1B | — | — | +181.3% | 0 |
| RZLT Rezolute, Inc. Common Stock (NV) | $374M | — | — | +85.7% | 58 |
| Peer median | $4.9B | — | +302.6% | +104.1% | 44 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
19.17M
SI % of Float
22.55%
Days to Cover
10.08
Short Vol Ratio
35.7%
Free Float
85.01M
Float %
87.9%
Short interest 2026-10-15 • Short volume 2026-11-10 • Float 2026-10-05